Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified BFM-95 for Newly Diagnosed T-LBL in Adults
NCT02396043Phase 2
Key facts
- Status
- Unknown
- Start
- Mar 2015
- Primary completion
- Mar 2025
- Countries
- 1
- Sponsor
- Sun Yat-sen University
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Conditions
- T-cell lymphoblastic lymphoma (T-LBL)
01
Overview
Phase 2, open-label trial of vincristine sulfate liposome injection, pirarubicin, prednisone, pegaspargase, cyclophosphamide and 4 more in T-cell lymphoblastic lymphoma (T-LBL), sponsored by Sun Yat-sen University. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Registry description
This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to modified BFM-95 regimen for acute lymphoblastic leukemia.
Beyond the preview
Go deeper on NCT02396043.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02396043.